Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
1999-09-03
2002-05-14
Huff, Sheela (Department: 1642)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C435S006120, C435S091200, C435S069100, C436S064000
Reexamination Certificate
active
06388065
ABSTRACT:
This invention relates to nucleic acid molecules suitable for evaluating the progression potential of cervical lesions, and to polypeptides encoded by such a nucleic acid molecules. Furthermore, this invention concerns antibodies directed against the polypeptides. Moreover, it covers the use of the nucleic acid molecules and the polypeptides as well as a kit suitable for evaluating the progression of cervical lesions.
Invasive cervical carcinoma usually follows from a precancerosis. Precanceroses cover a wide range of lesions referred to as mild to severe dysplasias (CIN1 to CIN3) pertaining to histopathology. CIN1 lesions frequently regress spontaneously and usually need not be treated. On the other hand, these lesions can persist over years or change into a more severe lesion, e.g. CIN3, or into a microinvasive carcinoma. A cytological method has been used for the diagnosis of cervical smears for about 50 years, by means of which dysplastic cells can be detected in cervical smears. This method is generally known as the “Pap test”. The “Pap test” contributed to the fact that the incidence of the cervical carcinoma could be reduced significantly in the past.
Several years ago, it was also found that the presence of dysplastic lesions and cervical carcinomas correlates with the detection of cervical carcinoma-associated human papilloma viruses, e.g. HPV 16 or HPV 18. The detection of antibodies against the viral HPV oncoproteins E6 and E7 in patient serum by means of ELISA or comparable methods is also possible as a detection of premalignant or malignant cervical diseases. It is also known that certain chromosomal deletions are associated with an increased risk of malignant transformation of the corresponding precancerosis. Morphological changes of cells and cell nuclei also correlate with malignant progression. These changes can be detected by means of cytometry.
Nevertheless, it is not possible by either the “Pap test” or the detection of oncogenic HPV types to make a prognosis regarding the further development of individual lesions. This also applies to the detection of HPV-specific antibodies in patient serum. By means of this serological method it is rather only possible to detect patients who already suffer from a carcinoma. Therefore, the antibody detection method cannot be considered a supplement to the present precaution but only to the manifestation of the finding that a carcinoma has developed already. In addition, the genetical analyses and cytometric approaches include the drawback that they are technically very complicated and therefore are not useful for routine diagnostics.
Therefore, it is the object of the present invention to provide a product by which the progressive potential of cervical lesions can be evaluated reliably.
This is the subject of the invention set forth in the disclosure which follows.
Thus, the subject matter of the present invention relates to an isolated nucleic acid molecule suitable for evaluating the progressive potential of cervical lesions. Such a nucleic acid molecule can be obtained by common methods. A method is preferred in which RNA from early and late passages of HPV-immortalized cells is isolated and the RNAs characteristic of the early passages and late passages, respectively, and expressed in markedly differing amounts, respectively, are identified and provided as DNA or RNA.
The present invention is based on the applicant's finding that late passages of HPV-immortalized cells cause tumors in naked mice, whereas early passages of such cells are not capable of doing so. The inventor also discovered that in late passages of HPV-immortalized cells certain RNAs are detected more strongly than is the case in early passages of such cells.
For the provision of a nucleic acid according to the invention RNA from early and late passages of HPV-immortalized cells are isolated. Early passages are e.g. passages 20-60, and late passages start from e.g. 130. For example, HPV 16-immortalized, human preputial keratinocytes, HPK-IA cells can be used as cells (cf. Dürst, M. et al., Oncogene 1/3 (1987), 251-256). The RNA of the early and late passages can be compared with each other and differences can be determined which are characteristic of the early passages and late passages, respectively. To this end, it is favorable to subject the RNA to reverse transcription. In this case, it is advantageous to use what are known as another primers, i.e. oligo-d(T) primers which following a sequence of 11-15 thymidine bases have two more bases at the 3′ end and thus recognize in well-known fashion the transition from the 3′ end of an mRNA to the poly-A tail where they bind. The resulting cDNA can be subjected to amplification in a PCR method. For this purpose, it is favorable to use common “arbitrary” primers together with the above anchor primers. The amplified cDNA can then be subjected to denatured polyacrylamide gel electrophoresis. In this step, cDNA bands are identified which have a differing intensity in the cDNA samples to be compared with one another, i.e. RNA isolates from the early and late passages of HPV-immortalized cells. These cDNA bands can be isolated from the gel and subjected to another round of amplification. Moreover, they can be cloned and their sequences can be determined. A person skilled in the art is familiar with the above methods. By way of supplement reference is made to the following literature (cf. Liang et al., Cancer Research 52, (1992), 6966-6968; Liang et al., Science 257, (1992), 967-971; Liang et al., Nucleic Acids Research 21, (1993), 3269-3275).
Both cDNA and RNA are examples of nucleic acid molecules in accordance with the invention, with cDNA. A (c)DNA which comprises a base sequence of
FIG. 1
or
FIG. 2
or a sequence differing therefrom by one or several base pairs is particularly preferred. The (c)DNA of
FIG. 1
was deposited as C4.8 with the DSMZ (Deutsche Sammlung von Miroorganismen und Zellkulturen) [Germany-type collection of microorganisms and cell cultures] under DSM 11197 on Oct. 4, 1996. Furthermore, the (c)DNA of
FIG. 2
was deposited as C21.7 with the DSMZ under DSM 11198 on Oct. 4, 1996. A nucleic acid molecule according to the invention is described as DNA by way of example below.
A DNA according to the invention can be present in a vector or an expression vector, respectively. The person skilled in the art is familiar with examples thereof. In the case of an expression vector for
E. coli
these include e.g. pGEMEX, pUC derivatives, pGEX-2T, pQE-8 and pet3d. For the expression in yeast e.g. pY100 and Ycpad1 have to be mentioned, while e.g. PKCR, pEFBOS, cDM8 and pCEV4 have to be indicated for the expression in animal cells. The baculovirus expression vector pAcSGHisNT-A is particularly suitable for the expression in insect cells.
The person skilled in the art knows suitable cells which express DNA according to the invention, which is present in an expression vector. Examples of such cells comprise the
E. coli
strains HB101, DH1, x1776, JM101, JM109, SG13009 and BL21, the yeast strain
Saccharomyces cerevisiae
and the animal cells L, 3T3, FM3A, CHO, COS, Vero and HeLa as well as the insect cells sf9.
The person skilled in the art knows in which way a DNA according to the invention has to be inserted in an expression vector. He is also familiar with the fact that this DNA can be inserted in combination with a DNA coding for another polypeptide, so that the DNA according to the invention can be expressed in the form of a fusion protein.
In addition, the person skilled in the art knows conditions of culturing transformed cells and transfected cells, respectively. He is also familiar with methods of isolating and purifying the polypeptide expressed by the DNA according to the invention. Thus, such a polypeptide, which may also be a fusion polypeptide, also represents a feature of the present invention. A polypeptide in accordance with the invention preferably comprises the amino acid sequence of
FIG. 1
or a sequence differing therefrom by one or several amino acids.
Dürst Matthias
Nees Matthias
Deutsches Krebsforschungszentrum Stiftung des Offentlichen Recht
Fulbright & Jaworski L.L.P.
Huff Sheela
Hunt Jennifer
LandOfFree
DNA for evaluating the progression potential of cervical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA for evaluating the progression potential of cervical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA for evaluating the progression potential of cervical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2893832